Bavarian Nordic's Pivot: Pandemic Profits Fuel a Travel Health Future

COPENHAGEN, Denmark – February 12, 2026 – Bavarian Nordic today revealed a financial narrative of two distinct realities: a record-breaking 2025 fueled by the waning mpox outbreak, and a more temperate 2026 forecast that signals a strategic pivot toward sustainable commercial growth. The Danish vaccine maker exceeded its 2025 revenue and profit guidance, but its outlook for the coming year reflects a deliberate shift in focus, prioritizing its booming travel health business at the expense of advancing its next-generation vaccine pipeline.

A Tale of Two Divisions

Bavarian Nordic reported preliminary, unaudited revenue of DKK 6,244 million for 2025, comfortably surpassing its latest guidance of approximately DKK 6,000 million. The impressive performance was driven by exceptional results from both of its core business units.

The Public Preparedness segment, which includes its crucial mpox and smallpox vaccine, JYNNEOS®, delivered DKK 3,105 million in revenue. This figure was more than DKK 1,000 million above its normal annual baseline, a direct consequence of sustained global demand as health authorities continued to bolster stockpiles in the wake of the 2022 mpox emergency. This windfall contributed significantly to the company's robust EBITDA margin of 41% (including a DKK 810 million one-time gain from the sale of a Priority Review Voucher).

Simultaneously, the Travel Health division proved to be a powerful engine of growth, demonstrating the success of the company's diversification strategy. The unit posted DKK 2,963 million in revenue, a remarkable 30% increase over 2024. This growth was anchored by strong sales of its established vaccines for rabies (Rabipur/RabAvert) and tick-borne encephalitis (TBE), which grew 34% and 20% respectively. Further validating its recent acquisitions, the company's first-year sales for its new chikungunya vaccine, Vimkunya, reached DKK 85 million, exceeding expectations.

“2025 was another strong year for Bavarian Nordic as we continued to scale our Travel Health business globally, which demonstrated a 30% growth year-over-year,” said Paul Chaplin, President and CEO of Bavarian Nordic, in the company's official statement. “These results are primarily driven by our core vaccines, rabies and TBE, but also supported by the successful launch of our chikungunya vaccine.”

Navigating the Post-Mpox Normal

While 2025 represented a peak, the guidance for 2026 paints a picture of normalization. The company projects total revenue to land between DKK 5,000 and DKK 5,200 million, a notable decrease from the previous year. The primary driver of this adjustment is the Public Preparedness business, which is expected to generate between DKK 1,800 and DKK 2,000 million. This marks a return to a more predictable, albeit less spectacular, revenue stream as the urgent demand for mpox vaccines subsides.

In contrast, the Travel Health division is forecast to continue its upward trajectory. The company expects approximately DKK 3,000 million in revenue from this segment. After accounting for the discontinuation of partnered product sales, this represents an underlying growth of 10%, or 14% at constant exchange rates—a healthy expansion that underscores the growing stability of this commercial pillar.

Chaplin's statement highlighted this strategic balance. “As outbreaks wane, we expect revenues from Public Preparedness to normalize in 2026. We remain however the leading provider to governments of mpox and smallpox vaccines to support their public health responses... and we continue to build strong partnerships with an aim to expand the base business.”

The Price of a Commercial Pivot

The strategic focus on bolstering the commercial portfolio comes with a significant trade-off. Bavarian Nordic announced it will cap its research and development spending at DKK 750 million for 2026. This budget prioritizes life-cycle management for its existing commercial products, including required follow-up studies for its new chikungunya vaccine.

Consequently, the company is delaying the advancement of its early-stage pipeline. Promising vaccine candidates for Epstein-Barr Virus (EBV) and Lyme disease, which were previously slated to enter clinical trials in 2026, are now pushed back to 2027. This decision could have long-term competitive implications. The race for a Lyme disease vaccine is particularly active, with competitors like Valneva and Pfizer potentially nearing regulatory submissions, and a delay could impact Bavarian Nordic's ability to capture a share of this emerging market.

The move signals a clear prioritization of near-term profitability and commercial execution over higher-risk, long-term scientific discovery. By channeling resources into its proven travel health assets, the company aims to build a more resilient and predictable financial base to offset the inherent volatility of its government-contract-driven public health business.

Charting a Course Through Acquisition

The strategic shift also sets the stage for the company's next chapter of growth, which is expected to be heavily influenced by mergers and acquisitions. CEO Paul Chaplin explicitly stated a desire to “further expand our portfolio to maximize our efforts globally,” which he noted would “strengthen our resilience towards the more unpredictable nature of our Public Preparedness business.”

This ambition comes after a tumultuous 2025, during which the company's board supported, but shareholders ultimately rejected, a takeover bid from a private equity consortium. The episode highlighted a consensus among leadership and potential investors that significant capital and strategic acquisitions are necessary to unlock the company's full value and diversify its revenue streams. With a fortified balance sheet from its 2025 performance and a clear mandate to reduce its reliance on outbreak-driven revenue, the market will be watching closely for Bavarian Nordic's next move. This strategic path, balancing immediate commercial needs against long-term innovation, will define Bavarian Nordic's trajectory in the evolving global vaccine market.